Teva’s Links to Opioid Epidemic May Triple Funding Costs

(Bloomberg) -- Teva Pharmaceutical Industries Ltd. may pay triple its usual borrowing costs for its planned $1.5 billion bond sale as investors demand more for holding its debt on account of its li...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.